Abbott Laboratories (ABT) EVP discloses share ownership and long-term options
Rhea-AI Filing Summary
Abbott Laboratories executive reports insider holdings
An executive vice president of Abbott Laboratories filed an ownership report as of 12/12/2025. The insider directly holds 63,621 common shares of Abbott Laboratories. In addition, the report lists several employee stock options granted under the Abbott Laboratories 2017 Incentive Stock Program, all classified as direct holdings.
The options cover blocks of Abbott common shares with exercise prices ranging from $75.90 to $135.42 per share and expiration dates from 02/21/2029 through 02/24/20352024 and 2028, reflecting the vesting schedules tied to long-term incentive compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Common shares without par value | -- | -- | -- |
Footnotes (1)
- Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,573 on February 21, 2025, 10,574 on February 21, 2026, and 10,574 on February 21, 2027. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,243 on February 25, 2026, 15,243 on February 25, 2027, and 15,244 on February 25, 2028.
FAQ
What insider position is reported for Abbott Laboratories (ABT)?
The filing shows an executive vice president of Abbott Laboratories as the reporting person, disclosing their beneficial ownership of Abbott securities as of 12/12/2025.
What stock options are reported by the Abbott (ABT) executive?
The report lists multiple employee stock options under the Abbott Laboratories 2017 Incentive Stock Program, each giving the right to buy Abbott common shares with different exercise prices and expiration dates.
What are the exercise prices and expirations of the reported Abbott (ABT) options?
Options cover Abbott common shares with exercise prices of $75.90, $79.98, $87.72, $124.04, $117.58, $106.24, $116.98, and $135.42, expiring between 02/21/2029 and 02/24/2035.
How do the Abbott (ABT) options vest under the 2017 Incentive Stock Program?
For certain grants, the filing specifies vesting in annual increments, such as 12,494/12,494/12,495 shares over three years, and similar three-year schedules like 10,573/10,574/10,574 and 15,243/15,243/15,244 shares.